9 articles, transcripts, and reports
Sage Therapeutics Inc (NASDAQ:SAGE) Q1 2023 Earnings Call dated May. 02, 2023. Corporate Participants: Helen Rubinstein — Director of Investor Relations Barry Greene — Chief Executive Officer Jim Doherty — Chief…
Sage Therapeutics Inc (NASDAQ: SAGE) Q4 2022 earnings call dated Feb. 16, 2023 Corporate Participants: Helen Rubinstein — Director of Investor Relations Barry Greene — Chief Executive Officer Jim…
Sage Therapeutics Inc (NASDAQ:SAGE) Q3 2022 Earnings Call dated Nov. 08, 2022. Corporate Participants: Helen Rubinstein — Director of Investor Relations Barry Greene — Chief Executive Officer Jeff Jonas — Chief…
Sage Therapeutics, Inc. (NASDAQ: SAGE) Q2 2022 earnings call dated Aug. 02, 2022 Corporate Participants: Helen Rubinstein — Director of Investor Relations Barry Greene — Chief Executive Officer Al…
Sage Therapeutics Inc. (NASDAQ: SAGE) Q1 2022 earnings call dated May. 03, 2022 Corporate Participants: Helen Rubinstein — Investor Relations Barry Greene — Chief Executive Officer Jim Doherty — Chief Development…
Sage Therapeutics, Inc. (NASDAQ: SAGE) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Helen Rubinstein — Investor Relations Officer Barry Greene — Chief Executive Officer Jim Doherty — Chief…
Sage Therapeutics Inc. (NASDAQ: SAGE) Q4 2020 earnings call dated Feb. 24, 2021 Corporate Participants: Jeff Boyle — Vice President, Head of Investor Relations Barry Greene — Chief Executive…
Sage Therapeutics Inc (NASDAQ: SAGE) Q2 2020 earnings call dated August 10, 2020 Corporate Participants: Jeff Boyle — Senior Director of Investor Relations Jeff Jonas — Chief Executive Officer…
— Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61. — Total revenue stood…
